NCT05836623 - A Phase I Study to Assess PSMA+ and PSMA- Tumour Lesions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

January 31, 2024

Study Completion Date

October 31, 2024

Conditions

Advanced and/or Metastatic Solid Tumours

Interventions

DRUG

Radiolabelled CB307

CB307 radiolabelled with 89-Zirconium (89Zr CB307): drug product is formulated at a concentration of 1 mg/mL (37 MBq)

DRUG

CB307

Trispecific Humabody® targeting CD137, prostate specific membrane antigen and human serum albumin

Trial Locations (1)

University Medical Center Groningen,, Groningen